Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course ...
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced that data from the ongoing Phase 1b study of R2891, a ...
A phase II open-label study of olutasidenib post-transplant maintenance therapy for patients with IDH1-mutated myeloid malignancies. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting ...
Myelodysplastic syndromes are a complex and heterogenous group of clonal myeloid neoplasms, characterised by ineffective ...
ScienceAlert on MSN
'Junk' DNA Could Be Recruited to Destroy Cancer Cells From Within
Sections of DNA once dismissed as dormant and useless could in fact be recruited to fight certain types of drug-resistant ...
Please provide your email address to receive an email when new articles are posted on . Individuals who smoked had more genetic mutations associated with myelodysplastic syndrome than nonsmokers.
TScan Therapeutics is laying off 30% of its workforce as the T-cell receptor (TCR) therapy biotech abandons a phase 1 solid ...
TipRanks on MSN
Bristol-Myers Squibb’s New Study on Myelodysplastic Syndrome: What Investors Need to Know
Bristol-Myers Squibb Company (($BMY)) announced an update on their ongoing clinical study. Study Overview: Bristol-Myers ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback